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Abstract 
Background: Prednisone dependence in asthma is usually described based on clinical and spirometric characteris‑
tics. It is generally believed that these patients have frequent exacerbations and lose lung function rapidly because of 
uncontrolled airway eosinophilia.
Objectives: The objectives of this study are to report the effect on asthma exacerbations and the change in lung 
function over time in prednisone‑dependent asthma when severe asthma is managed using a protocol that aims to 
maintain normal sputum cell counts.
Methods: A retrospective survey of patients prospectively assessed in a university tertiary care asthma clinic.
Results: 52 patients (30 males, mean age 51 years, 64% non‑atopic) were followed for a median period of 5.4 years 
(min–max: 0.2–35.2). Monitoring with the aim of keeping sputum eosinophils below 3% resulted in higher doses of 
corticosteroids (median daily dose of prednisone was 10 mg and for inhaled corticosteroids was 1500 μg of fluti‑
casone equivalent) than at baseline and this was associated with predictable adverse effects. Despite the disease 
severity, 10 patients (19%) did not require LABA for symptom control. Most importantly, over the period of follow‑up, 
there were only 0.3 eosinophilic exacerbations/patient/year. Overall, there was an increase in FEV1 over the period of 
follow‑up (mean +84.6 ml/year) rather than an expected decline.
Conclusions: Monitoring of eosinophils in sputum enables to maintain symptom control and preserve FEV1 in 
patients with severe prednisone‑dependent asthma.
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Background
Asthma management guided by sputum cell counts 
has been shown to reduce eosinophilic exacerbations 
[1, 2] and is cost-effective [3]. This is particularly true 
for patients with moderate to severe asthma as most 
patients with mild asthma may not require a biomarker-
guided treatment strategy [4]. However, it is not known 
if patients with the severest forms of asthma i.e. those 
that require daily prednisone would also benefit from 
a sputum-based management strategy. It is generally 
believed that these patients have frequent exacerbations, 
particularly those with persistent sputum eosinophilia 
[5] and that they lose lung function over time with each 
exacerbation [6]. These patients, although fortunately 
infrequent, consume the largest health care resources 
for asthma care [7]. They often have significant adverse 
effects from their doses of corticosteroids [8] and these 
are the patients who may benefit most with the advent of 
biologics that target the Th2 cytokine pathways [9].
The recent experience from the British Thoracic Soci-
ety Severe Asthma program suggest that the clinical 
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outcomes of patients with severe asthma are better if 
they are managed in specialized asthma centres than in 
general clinics [10]. A severe asthma clinic was set up 
at the Firestone clinic at St Joseph’s Healthcare in Ham-
ilton, ON in the early 1970s where patients were looked 
after by a respiratory physician (FEH) who was sup-
ported by a research staff of two technologists and one 
clinical trainee who was often a respiratory physician. 
The two unique features of this clinic were the introduc-
tion of quantitative cell counts in sputum to adjust initial 
treatment requirements and secondly (and more impor-
tantly) accessibility to these measurements within 72  h 
of any worsening of asthma symptoms. The main objec-
tives of this manuscript are to describe the effects of this 
strategy on FEV1 and on exacerbations in patients with 
prednisone-dependent asthma who were referred to this 
clinic.
Study design and methods
This was a retrospective descriptive chart review of 
patients with a physician-confirmed diagnosis of asthma 
(defined as episodic wheeze, chest tightness or shortness 
of breath and confirmed variable airflow obstruction of at 
least 12% and 200 ml improvement in FEV1 after inhaling 
200 mcg of salbutamol or a PC20 methacholine of <8 mg/
ml), and who were on a maintenance dose of at least 5 mg 
of prednisone daily for at least 6 months prior to the ini-
tial consultation, who were referred to a severe asthma 
clinic at the Firestone Institute in Hamilton, Ontario, 
between 1973 and 2008. Basic clinical and demographic 
data were documented. Pre-and post-bronchodilator 
reversibility were recorded according to the American 
Thoracic Society standards [11]. Airway responsive-
ness to methacholine was assessed by the tidal breathing 
method of Cockcroft et al. [12] if the FEV1 was >65% of 
predicted. Symptoms of cough, wheeze, chest tightness, 
dyspnea and sputum production were documented on 
a 7-point Likert scale (1 being worst and 7 being best). 
Tools to assess “asthma control” and “asthma-specific 
quality of life” were not available when the first patients 
were recruited into this program. Sputum was induced 
and processed according to the methods described by 
Pizzichini et al. [13].
Asthma was managed according to the protocol 
described by Jayaram et al. [1]. Briefly, the dose of inhaled 
corticosteroids or prednisone was increased to maintain 
sputum eosinophils less than 3% (or until free eosino-
phil granules were no longer present). If sputum total 
cell count was greater than 15 ×  106/g and neutrophils 
greater than 65%, the patients were treated with a broad 
spectrum antibiotic (zithromycin or amoxicillin + clavu-
lanic acid for 5–7  days). Most importantly, the dose of 
steroid was not increased. Long-acting bronchodilators 
(salmeterol or formoterol) were added to the inhaled ster-
oids only after the bronchitic component was controlled 
and the patient continued to have shortness of breath or 
wheezing that required more than 2–4 puffs of short-act-
ing bronchodilators daily. They were not added if spirom-
etry did not show any worsening of airflow obstruction 
or if PC20 methacholine was greater than 8  mg/ml or 
had not worsened by more than one doubling dose. If the 
sputum eosinophil % was less than 1%, the dose of cor-
ticosteroids was reduced. Sputum was always rechecked 
with 6–8 weeks of any treatment change. Once the main-
tenance dose of steroid was identified, patients were left 
on this dose indefinitely and seen in follow-up on aver-
age twice a year at which time spirometry, sputum and 
blood counts, clinical asthma control and adverse effects 
of therapy were assessed by self-reported history. Meth-
acholine airway responsiveness was also reassessed if 
patients reported an increase need for short-acting bron-
chodilators and the sputum cell counts were normal and 
if it was felt safe to perform the test (usually FEV1 > 65% 
predicted). Adherence to prescribed medications was 
continuously assessed by checking the pharmacy records 
every year.
If patients experienced any worsening of symptoms 
(increase in chest tightness or wheezing requiring at 
least four puffs of salbutamol daily or at night, increase 
in sputum production or change in colour to dark yel-
low or green) they were instructed to call our research 
office. Patients were brought to the clinic within 72 h for 
a clinical assessment, spirometry, and collection of either 
spontaneously expectorated or induced sputum. They 
were phoned back the same evening or the next morn-
ing with instructions to change their medication dosages. 
If patients had seen their family doctor and had received 
either antibiotics or prednisone without being seen at 
our clinic, this information was documented in the clinic 
chart. All the demographic and clinical information was 
meticulously extracted by a research assistant (AAR) and 
verified by a research technologist (MK) after obtaining 
approval from the Hospital Research Ethics Board.
Statistical analysis
Baseline demographic and clinical data were summarized 
using descriptive statistics. The rates of change of FEV1 
(ml/year) were analyzed by multilevel linear regression 
using three time points (at baseline, time when sputum 
quantitative assay became normal and at the most recent 
assessment) for each gender and smoking status sepa-
rately. As a first step, individual FEV1s were regressed 
against time to find rates of change (ml/year) for each 
patient. In the second step of multilevel linear regression, 
the rates of change (ml/year) for each patient (depend-
ent variable) were regressed with age and height as the 
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independent variables. The final rate of change of FEV1 
in a specific group e.g. males, females, smokers and non-
smokers was computed using the mean age and height 
of the respective groups. The analyses were carried out 
using SPSS (version 16). Since we did not have a compari-
son group of patients with milder asthma or patients with 
severe asthma who were not monitored using sputum 
cell counts, we plotted the rates of decline of our cohort 
against the data published by Ulrik et al. [14] for patients 
with mild asthma. Paired data were compared by Stu-
dent’s t test. P-value was considered significant if <0.05.
Results
The study included 52 (30 males and 22 females) patients. 
The baseline characteristics of all patients are tabulated 
in Table 1. The median time of follow up of all patients 
was 5.42 years (minimum 0.15, maximum 35.26).
Effect on sputum cell counts
Sputum eosinophil counts were normalized in all patients 
within a median period of 5 months (Table 2). This was 
associated with a trivial (but statistically significant) 
increase in sputum neutrophil % (Table  2; Fig.  1). The 
cell counts remained stable for the rest of the follow-up 
period.
Effect on FEV1
The rate of change of FEV1 from baseline value to the 
time point when sputum quantitative assay became nor-
mal was 1201.24  ml/year (95% CI 199.31 to 2202.7  ml/
year) while the rate of change (decline) from the time 
sputum was normal to the time when the patient was last 
seen was a modest −14.9 (95% CI 53.4 to −83.2) ml/year. 
The overall (baseline to when last seen) rate of change of 
FEV1 was 84.63 (95% CI −44.6 to 213.8) ml/year. The cor-
responding values in males were 970.53 (95% CI 178.5 to 
1762.4) ml/year, −28.36 (95% CI −18.1 to −38.6) ml/year 
and the overall rate of change was 113.99 (95% CI 70.6 
to 157.4) ml/year and for females were 1515.85 (95% CI 
−701.1 to 3732.7) ml/year, 3.44 (95% CI −115.7 to 122.6) 
ml/year and the overall rate of change was 44.59 (95% CI 
−95.6 to 184.8) ml/year. There were however no statisti-
cally significant difference between males and females in 
their rates of change of FEV1. The rates of change of FEV1 
for male smokers were : from baseline to when sputum 
was normal 1433.13 (95% CI 199.3 to 2666.9) ml/year, 
from when sputum was normal to when last seen 6.09 
(95% CI −113.1 to 125.3) ml/year and overall 227.31 (95% 
CI −91.9 to 546.5) ml/year and for females smokers were: 
Table 1 Baseline characteristics (n = 52)
Age, years (mean, SD) 51 (11)
Male (n) 30
Smoker (n) 28
Atopy (n, %) 19 (36%)
Chronic rhinosinusitis (n, %) 23 (45%)
Aspirin sensitivity (n, %) 9 (18%)
Age of onset of symptoms, years (median, min–max) 20 (9–45)
Years on prednisone prior to initial assessment (mean, SD) 7.2 (6.6)
Number of courses of prednisone over past 2 years/patient/
year (mean, SD)
1.8 (1.2)
Height, cm (mean, SD) 168.2 (10.2)
Weight, kg (mean, SD) 80.8 (14.4)
Serum IgE, KIU/l (mean, SD) 86 (18)
Blood eosinophil, ×103/l (mean, SD) 0.4 (0.5)
ICS, µg (median) 1500
LABA (n) 22
LTRA (n) 14
Table 2 Sputum, blood counts and spirometry (mean, SD) 
values
At initial  
visit




 Total cell count, 
×106/g
16 (24) 9 (11) 12 (8)
 Eosinophil, % 22 (18) 1 (4) 2.4 (4.2)
 Neutrophil, % 60 (49) 72 (28) 64 (20)
Blood
 Eosinophil count, 
×103/l
0.4 (0.5) 0.1 (0.2) 0.2 (0.3)
 Eosinophil % 6 (8) 4 (8) 4 (6)
Spirometry
 FEV1, L 2.3 (0.8) 2.5 (0.8) 2.2 (0.8)
 FEV1, % 70.7 (20.1) 76.9 (18.2) 69.4 (18.1)
 VC, L 3.6 (1.1) 3.6 (0.9) 3.4 (1.1)
 VC, % 88.7 (16.9) 90.9 (12.9) 84.4 (22.4)











TCC Eos Neutr TCC Eos Neutr




Fig. 1 Sputum cell counts at first visit, when eosinophils are normal‑
ized, and current
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from baseline to when sputum was normal 663.8 (95% CI 
−332.4 to 1660.0) ml/year, from when sputum was nor-
mal to when last seen 21.54 (95% CI −310.1 to 353.1) ml/
year and overall 82.58 (95% CI −306.6 to 471.8) ml/year. 
The corresponding values for male nonsmokers were: 
171.48 (95% CI −78.0 to 420.9) ml/year, −87.86 (95% CI 
−218.7 to 43.02) ml/year and −81.73 (95% CI −190.5 to 
27.1) ml/year and for female nonsmokers were: 2105.74 
(95% CI −1801.4 to 6012.9) ml/year, −9.09 (95% CI 
−35.3 to 17.2) ml/year and 18.28 (95% CI −11.4 to 47.9) 
ml/year. There were no statistical differences in rates of 
change of FEV1 between the genders when smokers and 
nonsmokers were analysed separately.
Effect on exacerbations
Over the 2 years prior to attending our clinic, the patients 
had reported an average of 1.9 exacerbations/patient/year 
that had responded to prednisone. Since sputum was not 
examined during these exacerbations, we cannot confirm 
that these were eosinophilic, but we assume they were as 
patients reported improvement in their asthma symptoms 
within 48–72 h of therapy. This was reduced to 0.3 eosino-
philic exacerbations/patient/year over the course of the fol-
low-up period. The average time of resolution of individual 
exacerbations was 4 days. We did not have accurate records 
of “non-eosinophilic” or “neutrophilic” exacerbations 
before their initial visit to our clinic. During the course of 
the follow-up, the patients had 1.2 neutrophilic exacerba-
tions/patient/year that were treated with antibiotics.
Effects related to corticosteroids
The median duration of the steroid optimization phase 
was 5  months (min–max 1–7  months). During this 
period, the median daily dose of prednisone was 10 mg 
(minimum 5  mg, maximum 35  mg) and the dose of 
inhaled corticosteroid was 1500 mcg of fluticasone equiv-
alent. This dose was maintained for the duration of the 
follow-up period. Five patients required the dose of pred-
nisone to be increased after the maintenance dose was 
established. Corticosteroids caused predictable adverse 
effects (Table 3) that were appropriately managed.
Effects related to LABA
At initial assessment, 22 patients were on LABA (15 
on salmeterol, 7 on formoterol). Over the course of the 
follow-up period, 20 patients were also commenced on 
LABA. The median period to commencement of LABA 
was 2 years (minimum 2 months, maximum 4 years). 10 
patients have not required LABA for symptom control 
as their asthma severity (and airflow obstruction) was 
largely driven by steroid-responsive luminal eosinophilic 
inflammation rather than by bronchodilator-responsive 
smooth muscle dysfunction.
Discussion
This retrospective study illustrates three important con-
cepts. Firstly, when available, incorporation of timely 
measurements of sputum quantitative cytometry and 
airway hyperresponsiveness into routine clinical prac-
tice is feasible and effective in the management of severe 
prednisone-dependent patients with asthma. Secondly, 
this strategy can reduce exacerbations and preserve lung 
function albeit at the cost of adverse effects of glucocor-
ticoids. Thirdly, recognition of the component of asthma 
that leads to severity can help to rationalize the inappro-
priate use of long-acting bronchodilators that are associ-
ated with asthma morbidity.
To our knowledge, this is the first study that reports 
the preservation of lung function in patients with severe 
asthma. Not only did we not observe the expected decline 
in FEV1 over time that has been reported in patients with 
“eosinophilic severe asthma” [5, 15], but there was a mod-
est improvement over the period of observation suggest-
ing that the current symptom-based guideline therapies 
underestimate the control of airway inflammation. We 
analysed longitudinal data using three time points i.e. 
when first seen, when sputum became normal and when 
a patient was last seen. The rate of change of FEV1 was 
positive when the rate was computed from the baseline 
value to the point when the airway inflammation (or 
the sputum quantitative assay) became normal (Fig.  2), 
whereas the rate of change of FEV1 thereafter, from the 
time sputum was normal to the time when the patient 
was last seen was a modest −14 ml/year which is clearly 
lesser than that reported in previous longitudinal asthma 
studies [6, 15–18]. The overall improvement in FEV1 in 
this study is possibly driven by the fact that most patients 
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Page 5 of 7Aziz‑Ur‑Rehman et al. Allergy Asthma Clin Immunol  (2017) 13:17 
had an improvement in lung function when sputum 
became normal after intensive anti-inflammatory therapy 
and that too within a short span of time resulting in high 
rates of improvement in FEV1 with time. Comparison 
with a matched group of patients at the Firestone clinic 
with similar severity of asthma who were managed based 
on symptoms only would have certainly added strength 
to the study. Unfortunately, such data were not available 
to us. However, it is extremely unlikely that treatment 
based on symptoms alone would give results similar to 
treatment using a sputum strategy [1].
Figure 2 illustrates a comparison of rates of change of 
FEV1 between this study and that by Ulrik et al. We fully 
realize that these two studies are not entirely comparable 
given the differences such as patient population, manage-
ment strategies, sampling strategies etc. [14]. However, 
most longitudinal asthma studies are population based 
observational reports. We selected the Ulrick study as 
this is one of the larger longitudinal asthma studies and 
employed a similar statistical analysis method to what we 
performed. Various factors such as gender, smoking, age 
of onset, atopy, sputum eosinophilia, presence of mucous 
hyper secretion and use of inhaled corticosteroids have 
been implicated as affecting the rate of change in FEV1 
in asthmatics. However, methodological issues have led 
to wide variations in these observations resulting in a lot 
of heterogeneity in the reported rates of decline in FEV1. 
Rates of decrease of FEV1 have varied from 25.7 ml/year 
in severe asthma [15], 31.5 ml/year in asthmatic patients 
with frequent exacerbations vs 14.6 ml/year in those with 
infrequent exacerbations [6], 26.6  ml/year in occupa-
tional asthmatics who were exposed to low-molecular-
weight sensitizers at work [16], 28.4–39.7 ml/year in adult 
nonsmoker asthmatic patients in the Busselton cohort 
[17], to 16.1–21.5  ml/year in asthmatic patients receiv-
ing inhaled corticosteroids [18]. In the current study, the 
rate of decline from when sputum was normal to when 
last seen is similar to the decline rate reported in asth-
matics with infrequent exacerbations [6]. Interestingly, 
in our study there were no statistical differences in rates 
of change of FEV1 either between the genders (Fig. 3) or 
when smokers and nonsmokers were analysed (Figs.  4, 
5) separately. Regardless of the fact that it may not be 
apt to compare studies with dissimilar populations and 
methodologies, we were able to demonstrate, perhaps 
Fig. 2 Mean FEV1 (with 95% CI) at three time points (when first 
seen, when sputum became normal, when last seen). Asterisk rates of 
decline are for the average age and height for the respective group
Fig. 3 Comparison of predicted (calculated) FEV1 vs time in 
years (Current Study vs Ulrik et al.). Dotted lines males, solid 
line females; predicted rates of decline and FEV1 for both stud‑
ies are for the mean age (males 52.4 years, females 49.8 years) 
and mean height (males 173.2 cm, females 161.4 cm) of the 
current study population. Equations for current study: FEV1 
at time t for males = (2.6795 − 0.03808*AGE +0.01124*HT) 
+(1.05455 − 0.00646*AGE −0.00348*HT)t; FEV1 at time t for fem
ales = (−4.27125 − 0.0253*AGE +0.04674*HT) + (−2.71234 − 0
.00336*AGE +0.01812*HT)t. Equations for Ulrik et al.: FEV1 at time 
t for males = (−469 − 35.2*AGE +32.0*HT) − (−107 − 0.79*AGE 
+0.6*HT + 1.7)t; FEV1 at time t for females = (−410 − 27.6*AGE 
+21.2*HT) − (−107 − 0.79*AGE +0.6*HT + 3)t
Fig. 4 Predicted (calculated) FEV1 vs time in years for males (Baseline 
to last seen) showing no statistical difference between smokers and 
nonsmokers; dashed line all patients, solid line smokers, dash and dot 
line nonsmokers. Predicted rates of decline and FEV1 are for the mean 
age and mean height for the respective group of the current study 
population
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for the first time, a strategy that did not use biologics that 
could preserve lung function even when asthma is severe. 
Only the eosinophilic inflammatory component could be 
effectively targeted with corticosteroids. We did not have 
any effective or specific strategy (other than antibiotics) 
to treat neutrophilic bronchitis. We speculate that lung 
function could perhaps have been better preserved had 
broader strategies effective against non-T2 type inflam-
mation as well been available for clinical use.
A second important point that we would like to high-
light in this report is that patients could be on high doses 
of corticosteroids and not necessarily require long-acting 
beta-agonists if the severity is driven by luminal inflam-
mation rather than by smooth muscle dysfunction. This 
is not often appreciated in clinical practice nor is it 
emphasized in the guidelines. In our cohort, the use of 
long-acting beta-agonist could be delayed or withheld in 
a small proportion of severe asthmatics in whom there 
is the highest concern for their adverse effects [19]. This 
also questions the veracity of recommendations to con-
sider anti-eosinophil biologics (such as mepolizumab or 
reslizumab) as steroid-sparing therapy only after adding 
long-acting bronchodilators [20] when long-acting beta-
agonists do not have any proven anti-eosinophil activi-
ties [21]. It is reasonable to consider biologics in patients 
whose disease are truly driven by eosinophils (as identi-
fied by persistent sputum eosinophils and blood eosino-
phils) and who have adverse effects from high doses of 
corticosteroids independent of their need for long-acting 
bronchodilators.
The major limitation of our study is the retrospective 
nature of data collection that spans over 25  years, the 
absence of a comparator group, and the lack of preci-
sion in the definition of exacerbations prior to referral to 
our clinic. It is also plausible that some of the exacerba-
tions may not have been reported to us during the period 
of follow up. We did not use any sophisticated method to 
assess compliance other than self reports and pharmacy 
logs.
Conclusion
In conclusion, we recommend monitoring of eosinophils 
in sputum in patients with severe prednisone-depend-
ent asthma as this strategy enables to maintain symp-
tom control, reduce exacerbations and preserve FEV1 in 
these patients. The test is not intrusive and is acceptable 
to most patients [22]. This study was performed before 
anti-IL5 monoclonal antibodies were available for clinical 
use but the results demonstrate that most patients would 
not require them for improving asthma control but they 
would be useful to avoid the adverse effects of corticos-
teroids. Our experience also provides ‘proof-of-princi-
ple’ that ‘remission’ [23] can be achieved even in severe 
asthma by judicious use of currently available therapy, 
albeit at the price of adverse effects of therapy.
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Fig. 5 Predicted (calculated) FEV1 vs time in years in females (Base‑
line to last seen) showing no statistical difference between smokers 
and nonsmokers; dashed line all patients, solid line smokers, dash and 
dot line nonsmokers. Predicted rates of decline and FEV1 are for the 
mean age and mean height for the respective group of the current 
study population
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